SCHEMBL313278

SCHEMBL313278

O=c1cc(-c2ccc(O)cc2O)oc2ccncc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.66
CYP3A4 P08684 6/20 0.66
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
CYP2C19 P33261 3/20 0.66
KDM4E B2RXH2 3/20 0.66
CYP2C9 P11712 2/20 0.66
TYR P14679 1/20 0.56
PTPN1 P18031 1/20 0.56
PTGS1 P23219 1/20 0.56
BACE1 P56817 1/20 0.56
PTPN12 Q05209 1/20 0.56
PTPN22 Q9Y2R2 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.53
TP53 P04637 4/20 0.53
ALOX15 P16050 3/20 0.53
QPCT Q16769 2/20 0.53
AKR1C3 P42330 1/20 0.50
AKR1C2 P52895 1/20 0.50
AKR1C1 Q04828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312877 0.89 HPGD (0.66) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL311162 0.83 MAPT (0.66) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL4650047 0.80 HPGD (1.00) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL6832163 0.79 HPGD (0.80) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL6241215 0.78 HPGD (0.70) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL311986 0.78 POLH (0.66) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL312060 0.77 HPGD (0.44) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL311738 0.77 HPGD (0.53) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL14697187 0.74 HPGD (0.65) HPGDCYP3A4MEN1KMT2ACYP2C19
SCHEMBL312688 0.74 BACE1 (0.55) HPGDCYP3A4MEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 HPGD 138/4885CYP3A4 1730/4885MEN1 4653/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 HPGD 138/4885CYP3A4 1730/4885MEN1 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.